Skip to main content
Premium Trial:

Request an Annual Quote

Boston Biomedica Wins $700K SBIR Grant to Commercialize PCT Technology

NEW YORK, March 14 - Boston Biomedica on Thursday said it has been awarded a $701,000 Phase II Small Business Innovation Research grant to help develop and commercialize its Pressure Cycling Technology.

The technology is used to "release DNA, RNA, and proteins from cells and tissues, with particular emphasis on hard-to-lyse biomaterials," Boston Biomedica said.

The money will also go toward studies of new life-sciences applications for the PCT sample preparation system, which the company will launch at Pittcon 2002  in New Orleans next week.

"This grant will permit BBI to further expand its usage to important applications in plant and animal genomics and proteomics, in addition to uses already under study, such as processing human tissues for cancer diagnosis or genetic abnormalities," Richard T. Schumacher, founder, chairman and CEO of Boston Biomedica, said in a statement.

According to Boston Biomedica, a "major advantage of the PCT sample preparation system over other methods is that PCT conditions can be controlled to preserve the activity of released material, including intact RNA and biologically active proteins, making it especially relevant for the study of gene expression."

This is the second Phase II SBIR grant the company has been awarded for its PCT technology. Last fall Boston Biomedica, of West Bridgewater, Mass., won $760,000 over two years to apply PCT "to the inactivation of viruses in blood plasma while preserving the plasma's therapeutic properties."

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.